Enphasys: Improved screening of the drug formulations of tomorrow
| Reference number | |
| Coordinator | Enphasys AB |
| Funding from Vinnova | SEK 900 000 |
| Project duration | June 2022 - November 2023 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 2 spring 2022 |
Important results from the project
Our was to further develop a miniaturized version of ENA (called mENA), which is a technology for studying drug absorption from the intestine. During the course of the project, validation of mENA with more advanced drug formulations has been carried out with positive results. Furthermore, the aim was to identify the production line for mENA. We have identified suitable green materials for production of mENA and identified the future industrial process for manufacturing of the same. We can now begin large-scale production of mENA for validation together with customers.
Expected long term effects
The main results are linked to the validation of mENA showing that the very complex set-up required to obtain in vivo relevant data can be miniaturized ~200 times and still provide valid data. Furthermore, through the solid analysis we made of the market, the competition and environmental aspects, we have identified the material, shape and size of the future product. Finally, we have identified production technology for our product and laid out a plan for how the process looks going forward, to start production on an industrial scale and enable validation with customers.
Approach and implementation
Our intention when we started was to work closely with consultants who are experts in their subject (materials, production, environment, etc.). However, it very soon turned out that we needed to have more knowledge ourselves to be able to communicate our technology, our needs and our wishes to said consultants. We also understood that we needed to check further around FTO and IP. Hence, we did a large part of the work ourselves, after which we used the information gathered in our discussions with consultants. We believe it was a wise strategic decision and are very pleased with the end result.